Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6842-6849

  Song, Jin ^a   Shih, Ie Ming ^a   Salani, Ritu ^a   Chan, Daniel W ^a   Zhang, Zhen ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN XI; CALCIUM BINDING PROTEIN; CISPLATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY MICROARRAY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANNEXINS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 36749063614     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0569     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
4. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol 2005;3:723-36.
5. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
6. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level [review]. Oncol Rep 2003;10:1663-82.
7. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
8. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997;57:850-6.
9. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993;71:1571-80.
10. Li X, Wang H, Touma E, Rousseau E, Quigg RJ, Ryaby JT. Genetic network and pathway analysis of differentially expressed proteins during critical cellular events in fracture repair. J Cell Biochem 2007;100:527-43.
11. Andersson O, Kozlowski M, Garachtchenko T, et al. Determination of relative protein abundance by internally normalized ratio algorithm with antibody arrays. J Proteome Res 2005;4:758-67.
12. Mishima M, Samimi G, Kondo A, Lin X, Howell SB. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002;38:1405-12.
13. Sreekumar A, Nyati MK, Varambally S, et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 2001;61:7585-93.
14. Yen MJ, Hsu CY, Mao TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006;12:827-31.
15. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 2001;61:903-7.
16. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-7.
17. Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003;9:5853-9.
18. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004;92:160-6.
19. Monastyrskaya K, Babiychuk EB, Hostettler A, Rescher U, Draeger A. Annexins as intracellular calcium sensors. Cell Calcium 2007;41:207-19.
20. Chetcuti A, Margan SH, Russell P, et al. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 2001;61:6331-4.
21. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001;98:9824-9.
22. Yeatman TJ, Updyke TV, Kaetzel MA, Dedman JR, Nicolson GL. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin Exp Metastasis 1993;11:37-44.
23. Stewart JJ, White JT, Yan X, et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 2006;5:433-43.
24. LeMoguen K, Lincet H, Deslandes E, et al. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-10. Proteomics 2006;6:5183-92.
25. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2006;58:384-95.
26. Fernandez MP, Jenkins NA, Gilbert DJ, Copeland NG, Morgan RO. Sequence and chromosomal localization of mouse annexin XI. Genomics 1996;37:366-74.
27. Furge LL, Chen K, Cohen S. Annexin VII and annexin XI are tyrosine phosphorylated in peroxovanadate-treated dogs and in platelet-derived growth factor-treated rat vascular smooth muscle cells. J Biol Chem 1999;274:33504-9.
28. Mamiya N, Iino S, Mizutani A, Kobayashi S, Hidaka H. Development-related and cell-type specific nuclear localization of annexin XI: immunolocalization analysis in rat tissues. Biochem Biophys Res Commun 1994;202:403-9.
29. Misaki Y, Pruijn GJ, van der Kemp AW, van Venrooij WJ. The 56K autoantigen is identical to human annexin XI. J Biol Chem 1994;269:4240-6.
30. Jorgensen CS, Levantino G, Houen G, et al. Determination of autoantibodies to annexin XI in systemic autoimmune diseases. Lupus 2000;9:515-20.
31. Farnaes L, Ditzel HJ. Dissecting the cellular functions of annexin XI using recombinant human annexin XI-specific autoantibodies cloned by phage display. J Biol Chem 2003;278:33120-6.
32. Williams LH, McClive PJ, Van Den Bergen JA, Sinclair AH. Annexin XI co-localises with calcyclin in proliferating cells of the embryonic mouse testis. Dev Dyn 2005;234:432-7.
33. Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 2003;162:255-61.
34. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000;83:83-8.
35. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, Georges E. Annexin-I expressionmodulates drug resistance in tumor cells. Biochem Biophys Res Commun 2004;314:565-70.
36. Hudelist G, Pacher-Zavisin M, Singer CF, et al. Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat 2004;86:281-91.
37. Fernandez-Madrid F, Tang N, Alansari H, et al. Autoantibodies to Annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res 2004;64:5089-96.